New and forthcoming anti-epileptic drugs

Paolo Prunetti, Emilio Perucca

Research output: Contribution to journalArticle

Abstract

Purpose of review: There is a need for newer anti-epileptic drugs (AEDs) with improved efficacy and tolerability. This article reviews AEDs introduced since 2007 and investigational compounds in clinical development. Recent findings: Two recently introduced AEDs, stiripentol and rufinamide, have been licensed exclusively for orphan indications, that is severe myoclonic epilepsy of infancy (stiripentol, Europe) and Lennox-Gastaut syndrome (rufinamide, Europe and the USA). This signals a welcome new trend to explore novel treatments in specific pediatric syndromes for which there are high therapeutic needs. Two additional AEDs, lacosamide and eslicarbazepine acetate, have been licensed recently for a more traditional indication, refractory partial-onset seizures. Although newly introduced agents given as adjunctive therapy have been found to be superior to placebo in reducing seizure frequency, the ultimate goal of sustained seizure freedom is rarely achieved. Therefore, the search for better agents should continue. Several investigational compounds are currently in various stages of clinical development. Summary: The recent introduction of newer AEDs has enlarged the armamentarium against epilepsy. However, newer agents had only a modest impact on the probability of achieving long-term remission. Novel strategies for the discovery and development of truly innovative AEDs are sorely needed.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalCurrent Opinion in Neurology
Volume24
Issue number2
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Pharmaceutical Preparations
Seizures
Myoclonic Epilepsy
Epilepsy
Therapeutics
Placebos
Pediatrics
rufinamide
stiripentol
Lennox Gastaut Syndrome
lacosamide
eslicarbazepine acetate

Keywords

  • clinical trials
  • epilepsy
  • new anti-epileptic drugs

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

New and forthcoming anti-epileptic drugs. / Prunetti, Paolo; Perucca, Emilio.

In: Current Opinion in Neurology, Vol. 24, No. 2, 04.2011, p. 159-164.

Research output: Contribution to journalArticle

Prunetti, Paolo ; Perucca, Emilio. / New and forthcoming anti-epileptic drugs. In: Current Opinion in Neurology. 2011 ; Vol. 24, No. 2. pp. 159-164.
@article{b1ca7b0a420440c6afcc96c428addf82,
title = "New and forthcoming anti-epileptic drugs",
abstract = "Purpose of review: There is a need for newer anti-epileptic drugs (AEDs) with improved efficacy and tolerability. This article reviews AEDs introduced since 2007 and investigational compounds in clinical development. Recent findings: Two recently introduced AEDs, stiripentol and rufinamide, have been licensed exclusively for orphan indications, that is severe myoclonic epilepsy of infancy (stiripentol, Europe) and Lennox-Gastaut syndrome (rufinamide, Europe and the USA). This signals a welcome new trend to explore novel treatments in specific pediatric syndromes for which there are high therapeutic needs. Two additional AEDs, lacosamide and eslicarbazepine acetate, have been licensed recently for a more traditional indication, refractory partial-onset seizures. Although newly introduced agents given as adjunctive therapy have been found to be superior to placebo in reducing seizure frequency, the ultimate goal of sustained seizure freedom is rarely achieved. Therefore, the search for better agents should continue. Several investigational compounds are currently in various stages of clinical development. Summary: The recent introduction of newer AEDs has enlarged the armamentarium against epilepsy. However, newer agents had only a modest impact on the probability of achieving long-term remission. Novel strategies for the discovery and development of truly innovative AEDs are sorely needed.",
keywords = "clinical trials, epilepsy, new anti-epileptic drugs",
author = "Paolo Prunetti and Emilio Perucca",
year = "2011",
month = "4",
doi = "10.1097/WCO.0b013e32834479a7",
language = "English",
volume = "24",
pages = "159--164",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - New and forthcoming anti-epileptic drugs

AU - Prunetti, Paolo

AU - Perucca, Emilio

PY - 2011/4

Y1 - 2011/4

N2 - Purpose of review: There is a need for newer anti-epileptic drugs (AEDs) with improved efficacy and tolerability. This article reviews AEDs introduced since 2007 and investigational compounds in clinical development. Recent findings: Two recently introduced AEDs, stiripentol and rufinamide, have been licensed exclusively for orphan indications, that is severe myoclonic epilepsy of infancy (stiripentol, Europe) and Lennox-Gastaut syndrome (rufinamide, Europe and the USA). This signals a welcome new trend to explore novel treatments in specific pediatric syndromes for which there are high therapeutic needs. Two additional AEDs, lacosamide and eslicarbazepine acetate, have been licensed recently for a more traditional indication, refractory partial-onset seizures. Although newly introduced agents given as adjunctive therapy have been found to be superior to placebo in reducing seizure frequency, the ultimate goal of sustained seizure freedom is rarely achieved. Therefore, the search for better agents should continue. Several investigational compounds are currently in various stages of clinical development. Summary: The recent introduction of newer AEDs has enlarged the armamentarium against epilepsy. However, newer agents had only a modest impact on the probability of achieving long-term remission. Novel strategies for the discovery and development of truly innovative AEDs are sorely needed.

AB - Purpose of review: There is a need for newer anti-epileptic drugs (AEDs) with improved efficacy and tolerability. This article reviews AEDs introduced since 2007 and investigational compounds in clinical development. Recent findings: Two recently introduced AEDs, stiripentol and rufinamide, have been licensed exclusively for orphan indications, that is severe myoclonic epilepsy of infancy (stiripentol, Europe) and Lennox-Gastaut syndrome (rufinamide, Europe and the USA). This signals a welcome new trend to explore novel treatments in specific pediatric syndromes for which there are high therapeutic needs. Two additional AEDs, lacosamide and eslicarbazepine acetate, have been licensed recently for a more traditional indication, refractory partial-onset seizures. Although newly introduced agents given as adjunctive therapy have been found to be superior to placebo in reducing seizure frequency, the ultimate goal of sustained seizure freedom is rarely achieved. Therefore, the search for better agents should continue. Several investigational compounds are currently in various stages of clinical development. Summary: The recent introduction of newer AEDs has enlarged the armamentarium against epilepsy. However, newer agents had only a modest impact on the probability of achieving long-term remission. Novel strategies for the discovery and development of truly innovative AEDs are sorely needed.

KW - clinical trials

KW - epilepsy

KW - new anti-epileptic drugs

UR - http://www.scopus.com/inward/record.url?scp=79953031818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953031818&partnerID=8YFLogxK

U2 - 10.1097/WCO.0b013e32834479a7

DO - 10.1097/WCO.0b013e32834479a7

M3 - Article

C2 - 21301338

AN - SCOPUS:79953031818

VL - 24

SP - 159

EP - 164

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 2

ER -